

Medtronic

Engineering the extraordinary

Medtronic plc

Q1 FY24

Earnings presentation

August 22, 2023



Medtronic

Forward looking statements

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties, including risks related to competitive factors, difficulties and delays inherent in the development, manufacturing, marketing and sale of medical products, government regulation and general economic conditions and other risks and uncertainties described in the company's periodic reports on file with the U.S. Securities and Exchange Commission including the most recent Annual Report on Form 10-K of the company, as filed with the U.S. Securities and Exchange Commission. Actual results may differ materially from anticipated results. Medtronic does not undertake to update its forward-looking statements or any of the information contained in this presentation, including to reflect future events or circumstances.

Non-GAAP financial measures

Certain information in this presentation includes calculations or figures that have been prepared internally and have not been reviewed or audited by our independent registered public accounting firm. Use of different methods for preparing, calculating or presenting information may lead to differences and such differences may be material. This presentation contains financial measures and guidance which are considered "non-GAAP" financial measures under applicable SEC rules and regulations. Medtronic management believes that non-GAAP financial measures provide information useful to investors in understanding the company's underlying operational performance and trends and to facilitate comparisons with the performance of other companies in the med tech industry. Non-GAAP financial measures should be considered supplemental to and not a substitute for financial information prepared in accordance with U.S. generally accepted accounting principles (GAAP), and investors are cautioned that Medtronic may calculate non-GAAP financial measures in a way that is different from other companies. Management strongly encourages investors to review the company's consolidated financial statements and publicly filed reports in their entirety. All GAAP to non-GAAP reconciliations are provided on our [website](#).

Medtronic calculates forward-looking non-GAAP financial measures based on internal forecasts that omit certain amounts that would be included in GAAP financial measures. For instance, forward-looking organic revenue growth guidance excludes the impact of foreign currency fluctuations, as well as significant acquisitions or divestitures. Forward-looking diluted non-GAAP EPS guidance also excludes other potential charges or gains that would be recorded as Non-GAAP Adjustments to earnings during the fiscal year. Medtronic does not attempt to provide reconciliations of forward-looking non-GAAP EPS guidance to projected GAAP EPS guidance because the combined impact and timing of recognition of these potential charges or gains is inherently uncertain and difficult to predict and is unavailable without unreasonable efforts. In addition, the company believes such reconciliations would imply a degree of precision and certainty that could be confusing to investors. Such items could have a substantial impact on GAAP measures of financial performance.

Financial comparisons

References to results increasing, decreasing, or remaining flat are in comparison to the same period in the prior fiscal year. References to organic revenue growth exclude the impact of significant acquisitions or divestitures and currency. Unless stated otherwise, quarterly and annual rates and ranges are given on an organic basis. References to sequential revenue changes are made on an "as reported" basis. Unless stated otherwise, all references to share gains or losses are as of the most recently completed calendar quarter, on a revenue basis, and in comparison to the same period in the prior year.



Table of contents



Q1 FY24 Executive Summary

Q1 FY24 Key messages

Solid results bolstered by combination of improving underlying fundamentals, innovation and execution

Broad-based performance generated results ahead of expectations
Accelerating top-line organic growth of 6.0% benefitted from continued procedure volume recovery, supply chain improvements, and innovative product launches; EPS of \$1.20 reflected successful efforts to mitigate macro-headwinds

Attractive mix of secular growth businesses amplified by HSD geographic strength

- Combined HSD growth for Established Market Leaders: Cardiac Rhythm Management, Spine & Surgical
- Strength in Highest Growth OUs led by Structural Heart and ex-U.S. Diabetes with continued underlying momentum across the balance of high growth businesses adding confidence to top-line durability
- Notable contributions in our Synergistic businesses include Aortic, ENT, Cardiac Surgery & Neuromod
- Breadth of geographic strength: HSD growth in Non-U.S. Developed & Emerging Markets; MSD in U.S.

Fundamentals benefitting from end markets and ongoing transformation
Sustained procedure recovery, innovative product launches and improved supply chain contributing to Q1 performance. Comprehensive transformation taking hold - upgrading capabilities, heightened accountability, streamlined portfolio and decisive capital allocation; all designed to deliver durable growth

Raising FY24 guidance
Encouraged by Q1 performance and added visibility of new growth drivers while actively mitigating known macro headwinds impacting both profitability and cash flow. Raising FY24 guidance: organic revenue growth 4.5%; EPS \$5.08 - \$5.16, a 7 cent raise at the midpoint, inline with Q1 operational beat

Confident in delivering durable revenue growth and shareholder value
Focused on delivering our pipeline, decisively allocating capital and improving our operational health as part of our commitment to a performance-driven culture


// We had a strong start to our fiscal year. We executed and delivered another quarter of mid-single digit revenue growth.
We also continue to make great strides on our comprehensive transformation designed to ensure durable growth and create value for shareholders.

**GEOFF MARTHA,
CHAIRMAN & CEO**




Q1 FY24 Financial summary

Revenue¹ by segment



Revenue¹ by geography




	GAAP	Non-GAAP	Cash flow from operations YTD
Diluted EPS	\$0.59	\$1.20	\$0.9B
Y/Y %	-16%	+6%	Free cash flow ² YTD
CC Y/Y %	N/A	+13%	\$0.5B

1) Data has been intentionally rounded to the nearest million and, therefore, may not sum.
 2) Operating cash flows less property, plant, and equipment additions.

Q1 FY24 Regional organic revenue growth

Breadth of performance with HSD growth in Non-U.S. Developed Markets and Emerging Markets and MSD in the U.S.

United States **Non-U.S. Developed** ▲ 7.2%



▲ 4.7%

Western Europe



▲ High-single digits

Japan



▲ Low-single digits

Australia & New Zealand



▲ Low-double digits

Canada



▲ Low-single digits

South Korea



▲ Low-double digits

Emerging Markets ▲ 7.7%

China



▲ Mid-single digits

Middle East & Africa




▲ Mid-teens

Latin America



▲ High-teens

Eastern Europe



▼ High-teens

Southeast Asia



▲ Mid-teens


South Asia



▲ High-teens

Key product approvals

Last 12 months: ~125 product approvals in key geographies¹



Note: Relative positioning is not intended to signify relative timing

1) Includes U.S., EU, Japan and China. Does not include all indication or partner approvals, though select additional approvals are displayed

Q1 FY24 Portfolio Highlights

Cardiovascular

6% growth driven by strong performance in Pacing, TAVR, Aortic & Cardiac Surgery

Cardiac Rhythm & Heart Failure (CRHF)

- Cardiac Pacing Therapies: MSD growth; mid-teens WW Micra™ growth driven by OUS adoption and U.S. launch of Micra AV2 and VR2; mid-40s WW SelectSure™ 3830 lead growth, the only lead approved for conduction system pacing in the U.S.
- Defibrillation Solutions: MSD implantables growth; initiating Aurora EV-ICD™ Western Europe limited market release in Q2
- Diagnostics: MSD growth driven by LINQ II™ global launches including AccuRhythm™ AI 2.0 in the U.S.
- CAS: MSD growth driven by Arctic Front™ cryoablation catheters; Affera™ mapping and ablation system limited market release in Europe underway; PulseSelect™ PFA catheter under FDA review

Structural Heart & Aortic (SHA)

- Structural Heart (TAVR): LDD growth driven by Evolut™ FX, along with SVD Durability Data showing CoreValve™ and Evolut™ as the first and only TAVR platforms to outperform SAVR at 5 years
- Aortic: LDD growth on supply improvements and AAA share gains driven by excellent 10-year Endurant data release
- Cardiac Surgery: mid-teens U.S. growth driven by strength in Cannula & Perfusion

Coronary and Peripheral Vascular (CPV)

- Coronary: Y/Y DES share gains driven by Onyx Frontier™ launch; MSD growth in Guide Catheters and LSD growth in Balloons
- Peripheral Vascular Health: LDD growth in DCBs driven by strength of IN.PACT™ 018 DCB; LDD growth in Vascular Embolization and HSD growth in Superficial Venous

Micra™ AV2 and VR2
Transcatheter
Pacing System




LINQ II™
Insertable
Cardiac Monitor



Arctic Front™
cryoablation
catheters



Evolut™ FX
TAVR System



IN.PACT™ 018
DCB



21%

CPV | \$589M
+1.7% Y/Y Rep
+3.1% Y/Y Org

\$2,850M

+5.5% Y/Y Rep
+6.2% Y/Y Org

28%

SHA | \$814M
+9.9% Y/Y Rep
+10.5% Y/Y Org

51%

CRHF | \$1,446M
+4.7% Y/Y Rep
+5.2% Y/Y Org

Operating Unit Growth

Cardiac Rhythm Management	▲	MSD
Cardiac Ablation Solutions	▲	MSD
Structural Heart & Aortic	▲	LDD
Cardiac Surgery	▲	HSD
Coronary	▲	LSD
Peripheral Vascular Health	▲	MSD

1) Aurora EV-ICD™, Affera™ and PulseSelect™ are not available in the U.S.

Neuroscience

6% growth with strength in Spine & Biologics and ENT

Cranial & Spinal Technologies (CST)

- HSD Spine & Biologics growth, including in the U.S., on implant and biologic pull-through fueled by Aible™
- Neurosurgery: MSD growth overall, with LDD growth in Enabling Tech and record OUS StealthStation™ and Mazor™ sales (HSD and LDD growth, respectively), partially offset by continued shift to alternative financing models in large capital
- Continued adoption of the Aible™ Spinal Ecosystem with its AI enabled surgical planning, implants, navigation, robotics, interoperative imaging, and surgical tools

Specialty Therapies (ST)

- Neurovascular: LSD growth (MSD ex-China given coils VBP) with growth fueled by flow diversion and strong adoption of Shield Technology™
- Ear, Nose & Throat: High-teens growth driven by strong disposable run rates and continued improvement in product availability
- Pelvic Health: ~Flat ex. Enterra divestiture; healthy market growth with competitive pressure; solid WE growth due to recent InterStim X™ launch

Neuromodulation (NM)

- Spinal Cord Stimulation: MSD growth driven by increasing trialing and implanting rates of our differentiated DTM™ on Intellis™ platform
 - Just received CE Mark approval for our next-generation spinal cord stimulator, Inceptiv™, which will be available in Europe in the coming months
- Brain Modulation: MSD growth supported by strong new implant rates of Percept™ PC with BrainSense™ technology, offsetting replacement headwinds



Aible™
Surgical Ecosystem


Pipeline™ Shield
Embolization Device
with Shield Technology™



DTM™ SCS
on the Intellis™
platform



Percept™ PC
with BrainSense™
technology



Operating Unit Growth

Cranial & Spinal Technologies	▲	MSD
Neurovascular	▲	LSD
ENT	▲	High-teens
Pelvic Health	■	~Flat ¹
Neuromodulation	▲	MSD


1) Pelvic Health OU growth shown ex. Enterra divestiture
11 | Q1 FY24 Earnings Presentation | August 22, 2023

Medical Surgical

6% growth driven by Advanced Surgical, Hugo™ momentum continues

Surgical & Endoscopy² (SE)

- Surgical: HSD growth benefitted from product availability and improved procedure volumes; Strength in Advanced Energy extended recent share recovery with continued growth in V-Loc™ barbed sutures
 - Key technology expansion continues in Advanced Energy, highlighted by LigaSure™ XP Maryland Jaw Sealer/Divider launch across U.S., WE, and ANZ
 - Hugo™ installs increased and momentum continued, JPN launch off to a good start with continued expansion to other markets; activated new sites in our Expand URO U.S. pivotal trial, which continues to progress as planned
- Endoscopy: MSD WW growth led by strength in procedure volumes and key revenue contributions from Barrx™ supply recovery as well as continued strength in GI Genius™ and PillCam™



Patient Monitoring & Respiratory Interventions (PMRI)

- Patient Monitoring: MSD growth driven by LDD growth in Perioperative Complications, and strong performance in Nellcor™ pulse oximetry monitors fueled by launch of RespArray™
- Respiratory Interventions: MSD growth driven by HSD Airways performance and market share gains; Low-30s growth in Video Laryngoscopy led by continued strength in McGRATH™
- Continue to target the intended separation of PMRI through a likely spinoff in the first half of fiscal year 2025



Operating Unit Growth


Surgical	▲	HSD
Endoscopy	▲	MSD
Patient Monitoring	▲	MSD
Respiratory Interventions	▲	MSD

1) Hugo™ is not available in the U.S.
2) Endoscopy was formerly called the Gastrointestinal business

Diabetes

High-teens Non-U.S. Developed Market growth on strength of MiniMed™ 780G system; U.S. launch exceeds expectations with low 30s pump growth

- U.S. turnaround underway driven by strong adoption of MiniMed™ 780G system, the only system with Meal Detection™ technology and automatic adjustments & corrections every 5-minutes
 - Best quarter in over 3 years for new patient adoption; attrition levels reversing
 - True 2nd gen Automated Insulin Dosing (AID) algorithm fueling rapid adoption with over 50% of U.S. MiniMed™ 770G installed base upgrading or placing orders since launch
 - Coverage secured for over 95% of patients, including expanded access for Medicare in July; 30% increase in prescribing HCPs since ADA congress in June
 - MiniMed™ 780G system automation benefits driving full system sales, with very high CGM attachment and Extended Infusion Set (EIS) utilization
- Sustained momentum in Non-U.S. Developed markets with high-teens growth - highest in 4 years - driven by mid-teens pump growth and high-20s CGM growth
 - Western Europe growing high-teens; winning ~40% of new starts in top 6 markets with direct competition
 - CGM attachment steadily increasing expanding with Guardian™ 4 sensor now available in 60+ countries
 - Continued reimbursement benefit in EU underscores value of AID with expanded reimbursement in Australia, sustaining adoption of Smart Dosing technologies
- Increased investment in clinical studies for expanded indications; meeting aggressive timelines for MiniMed™ 780G + Simplera™ IDE enrollment: adult enrollment complete in Q1 with pediatric enrollment on track for Q2 completion



MiniMed™ 780G system
global real-world data achieves
~80% TIR¹



Simplera™
Next gen CGM
currently under
FDA and CE Mark
review



EOFlow Acquisition
remain on track to close
acquisition in H2 CY23

1) 79% Time In Range using recommended settings as shown in real-world evidence for MM780G system (n=5,762)

Q1 FY24 Financial Highlights

Q1 FY24 Income statement

GAAP¹

(\$ in millions)	Q1 FY23	Q1 FY24	Y/Y
Revenue	\$7,371	\$7,702	4.5%
Gross Margin	65.9%	65.9%	flat
SG&A % of Sales	34.8%	33.9%	-90 bps
R&D % of Sales	9.4%	8.7%	-70 bps
Operating Margin	15.3%	16.5%	120 bps
Net Income	\$929	\$791	-14.9%
Diluted EPS	\$0.70	\$0.59	-15.7%

Full GAAP to non-GAAP reconciliation in Appendix

Non-GAAP¹

(\$ in millions)	Q1 FY23	Q1 FY24	Y/Y
Revenue	\$7,371	\$7,702	4.5%
Gross Margin	66.5%	66.4%	-10 bps
SG&A % of Sales	34.2%	33.4%	-80 bps
R&D % of Sales	9.2%	8.5%	-70 bps
Operating Margin	23.9%	24.8%	90 bps
Net Income	\$1,502	\$1,596	6.3%
Diluted EPS	\$1.13	\$1.20	6.2%

1) The data in this table has been intentionally rounded and, therefore, may not sum; Dollars in millions except for EPS.

Exercising decisive capital allocation

Prioritizing innovation-driven growth investments while delivering consistent dividend returns to shareholders

Investments for Growth

Research & Development

Target R&D growth at/above revenue growth

5% CAGR

Fiscal Year	R&D Investment
FY20	\$2.3B
FY23	\$2.7B

Smart M&A

Focus on tuck-in M&A with heightened focus on market selection

10 Acquisitions since FY21

>\$4.0B in total consideration since FY21

Minority investments, strategic partnerships, & incubators

Add to traditional investment

Blackstone

\$1.6B invested as of Q1 FY24

.....>

80+ companies

Dividend & Share Repurchase

Target minimum of 50% of Free Cash Flow returned to shareholders annually; prioritizing dividends

FY23

\$4.0B Net share repurchases & dividends

86% of Free Cash Flow

46 Years of dividend increases

Member of **S&P 500 Dividend Aristocrats**

\$4.0B shares repurchased since FY21

Return to Shareholders

Guidance & Assumptions

Guidance and assumptions

FY24 REVENUE	FY23 base ¹	Organic revenue growth guidance	FX ³	Inorganic	Other ²	Implied reported revenue range
Q4 Earnings Call May 25, 2023	FY23 Reported \$31,227M	4.0% to 4.5%	+\$110M to +\$210M	\$0	~\$50M	~\$32.0B to \$32.3B
	Less IP Agreement (\$265M)					
Q1 Earnings Call August 22, 2023	Less Other ² (\$300M)	4.5%	(\$25M) to +\$75M	\$0	~\$50M	~\$32.1B to \$32.2B
	FY23 base \$30,662M					

FY24 EPS	FY23 base	Implied constant currency growth	FX ²	FY24 EPS guidance
Q4 Earnings Call May 25, 2023		+1% to +3%	~(6%)	\$5.00 to \$5.10
	\$5.29			
Q1 Earnings Call August 22, 2023		+2% to +3%	~(6%)	\$5.08 to \$5.16

Note: EPS guidance does not include any charges or gains that would be reported as non-GAAP adjustments to earnings during the fiscal year

1) FY23 reported revenue of \$31,227 less IP Agreement of \$265M and less Other of \$300M

2) Other includes Mozarc Medical and Cardinal Health Manufacturing Agreements

3) While FX rates are fluid, assumptions above are based on rates as of the beginning of May 2023



Sustainability

Sustainability

Leading in engagement, citizenship and innovation



DiversityInc

#2 in Diversity Top 50, #2 for Mentorship, #7 for Supplier Diversity, #5 for ESG, #1 for Top company for executive women, #1 for Latino executives, #4 for Asian American executives



2022 Great Place To Work® And Fortune Magazine
 #12 Worlds Best Workplaces™



Great Place to Work® certified awarded to Medtronic in Australia, Greater China, Spain, and 20 other countries



Human Rights Campaign
 100% Corporate Equality Index Human Rights Campaign - Best Places to Work for LGBTQ+ in South America - Medtronic Chile

Member of
Dow Jones Sustainability Indices
 Powered by the S&P Global CSA

Dow Jones Sustainability Index
 DJSI World Index for 2 consecutive years
 DJSI North American Index for 15 consecutive years



Top Employers Institute certified

Awarded to Medtronic in the U.K., Egypt, South Africa, and 6 other countries



Ethisphere

One of the 2023 Worlds Most Ethical Companies®



2023 Disability:IN and the American Association of People with Disabilities Disability Equality Index® Best Places to Work™ – 100% Score 6th consecutive year with top score



2022 Hispanic Association on Corporate Responsibility Corporate Inclusion Index
 Medtronic received 5-star awards across all four pillars – Employment, Philanthropy, Procurement, and Governance – one of only two companies to do so in 2022



3BL Media

Placed 41st on 2022 100 Best Corporate Citizens for 6 consecutive years

Named one of America's 2022
Best Employers for Veterans
 by Forbes

Forbes

America's Best Employers for Veterans 2022



Glassdoor

Best Places to Work 2022



Just Capital

Named one of America's Most JUST Companies by JUST Capital



2022 India's Best Workplaces for Women Medtronic Engineering and Innovation Centre in Hyderabad



IR Magazine

2023 Best IR Website; Runner-up for Best IR in Healthcare

Sustainability

Long-range objectives & targets



For more information, visit [Medtronic.com](https://www.medtronic.com)
2021 ESG Investor Briefing
2022 Integrated Performance Report
2022 Global Inclusion, Diversity & Equity Report

Patient Safety & Product Quality

10%

Reduction in aggregate product complaint rate for identified product families by FY25 vs. FY20

Access & Innovation

20%

MDT revenue from products and therapies released in the prior 36 months by FY25

85M

Patients served annually by FY25

Inclusion, Diversity & Equity

45%

Global management positions held by women by FY26

30%

U.S. management positions held by ethnically diverse talent by FY26

Climate Stewardship

50%

Reduction in greenhouse gas omission intensity by FY25

50%

Sourced energy from renewable and alternative sources by FY25

Carbon Neutral

In our operations by FY30

Net Zero Emissions

By 2045


Product Stewardship

25%

Reduction in packaging waste for targeted high-volume products by FY25 vs. FY21

35%

Reduction in paper associated with Instructions for Use (IFUs) by FY27 vs. FY21



Appendix

Q1 FY24 Revenue by portfolio and geography

	Worldwide			U.S.			Non-U.S. Developed			Emerging Markets		
	Revenue (\$M) ¹	As reported Y/Y%	Organic Y/Y%	Revenue (\$M) ¹	As reported Y/Y%	Organic Y/Y%	Revenue (\$M) ¹	As reported Y/Y%	Organic Y/Y%	Revenue (\$M) ¹	As reported Y/Y%	Organic Y/Y%
Cardiovascular	2,850	5.5%	6.2%	1,350	5.0%	5.0%	956	7.2%	7.0%	544	4.0%	8.0%
Cardiac Rhythm & Heart Failure	1,446	4.7%	5.2%									
Structural Heart & Aortic	814	9.9%	10.5%									
Coronary & Peripheral Vascular	589	1.7%	3.1%									
Neuroscience	2,219	4.9%	5.6%	1,497	5.5%	5.5%	416	2.2%	3.2%	306	5.5%	9.3%
Cranial & Spinal Technologies	1,103	5.8%	6.4%									
Specialty Therapies	695	4.2%	5.4%									
Neuromodulation	420	3.7%	3.7%									
Medical Surgical	2,039	5.5%	6.1%	881	6.0%	6.0%	772	5.0%	5.9%	386	4.9%	6.5%
Surgical & Endoscopy	1,546	6.3%	6.7%									
Patient Monitoring & Respiratory Interventions	493	2.9%	3.8%									
Diabetes	578	6.8%	6.3%	188	-8.7%	-8.7%	315	19.3%	17.8%	75	4.2%	6.9%
Other	16	-80.2%	-	8	-68.0%	-	5	-84.4%	-	3	-87.5%	-
Total Medtronic	7,702	4.5%	6.0%	3,924	4.2%	4.7%	2,463	5.8%	7.2%	1,314	3.0%	7.7%

1) Data has been intentionally rounded to the nearest million and, therefore, may not sum
 23 | Q1 FY24 Earnings Presentation | August 22, 2023

Q1 FY24 GAAP to non-GAAP reconciliations

	Q1 FY24 GAAP	Amortization	Restructuring	Certain Litigation	Acquisition and Divestiture- Related Items	(Gain) / Loss on Minority Investment	Medical Device Regulations	Certain Tax Adjustments	Q1 FY24 Non-GAAP	Q1 FY23 Non-GAAP	Y/Y Growth / Change
Net Sales	7,702	-	-	-	-	-	-	-	7,702	7,371	4.5%
Cost of Products Sold	2,628	-	(16)	-	(6)	-	(21)	-	2,586	2,467	4.8%
Gross Margin	65.9%	-	0.2%	-	0.1%	-	0.3%	-	66.4%	66.5%	-10 bps
SG&A	2,613	-	(21)	-	(16)	-	-	-	2,575	2,518	2.3%
% of Sales	33.9%	-	(0.3%)	-	(0.2%)	-	-	-	33.4%	34.2%	-80 bps
R&D	668	-	-	-	-	-	(10)	-	658	678	(2.9%)
% of Sales	8.7%	-	-	-	-	-	(0.1)%	-	8.5%	9.2%	-70 bps
Other Operating Expense (Income), Net	1	-	1	-	(27)	-	31	-	(26)	(57)	(54.4%)
% of Sales	-	-	-	-	(0.4)%	-	-	-	(0.3)%	(0.8)%	50 bps
Amortization of Intangible Assets	429	(429)	-	-	-	-	-	-	-	-	-
Restructuring Charges, Net	54	-	(54)	-	-	-	-	-	-	-	-
Certain Litigation Charges	40	-	-	(40)	-	-	-	-	-	-	-
Operating Profit	1,268	429	91	40	50	-	31	-	1,909	1,765	8.2%
Operating Margin	16.5%	5.6%	1.2%	0.5%	0.6%	-	0.4%	-	24.8%	23.9%	90 bps
Other Non-Operating Income, Net	(76)	-	-	-	-	(64)	-	-	(141)	(79)	78.5%
Net Income Attributable to MDT (\$M)	791	364	76	31	46	64	25	198	1,596	1,502	6.3%
Diluted EPS (\$)⁽¹⁾	0.59	0.27	0.06	0.02	0.03	(0.05)	0.02	0.15	1.20	1.13	6.2%

1) Data has been intentionally rounded to the nearest million or \$0.01 for EPS figures and, therefore, may not sum

FY24 Medtronic business structure



Cardiovascular

[Learn more](#)

- Cardiac Rhythm & Heart Failure**
 - Cardiac Rhythm Management*
 - Cardiac Ablation Solutions
- Structural Heart & Aortic**
 - Structural Heart & Aortic
 - Cardiac Surgery
- Coronary & Peripheral Vascular**
 - Coronary & Renal Denervation
 - Peripheral Vascular Health



Neuroscience

[Learn more](#)

- Cranial & Spinal Technologies**
- Specialty Therapies**
 - Neurovascular
 - Ears, Nose & Throat (ENT)
 - Pelvic Health
- Neuromodulation**



Medical Surgical

[Learn more](#)

- Surgical & Endoscopy**
 - Surgical
 - Endoscopy**
- Patient Monitoring & Respiratory Interventions**
 - Patient Monitoring*
 - Respiratory Interventions



Diabetes

[Learn more](#)

Therapies and services for insulin-dependent people who have Type 1 and Type 2



Other

[Learn more](#)

- Mozarc Medical Manufacturing & Servicing Agreements
- Cardinal Health Manufacturing Agreements***

* Medtronic Care Management Services reported as part of Cardiac Rhythm Management in FY23 moved to Patient Monitoring for FY24
 ** Endoscopy was formerly called the Gastrointestinal business
 *** Previously included within Medical Surgical Portfolio
 25 | Q1 FY24 Earnings Presentation | August 22, 2023

Abbreviations & acronyms

Growth		Business specific		Business specific		Other	
▼	Revenue Decreased Y/Y Organic	AAA	Abdominal Aortic Aneurysm	ICD	Implantable Cardioverter Defibrillator	ADA	American Diabetes Association
—	Revenue flat Y/Y Organic	CGM	Continuous Glucose Monitoring	PFA	Pulse Field Ablation	Ex-Vent	Excluding Ventilator
▲	Revenue Increased Y/Y Organic	CRM	Cardiac Rhythm Management	RAS	Robot-Assisted Surgery	HCP	Health Care Provider
WAMGR	Weighted Average Market Growth Rate	CRT-D	Cardiac Resynchronization Therapy - Defibrillator	SAVR	Surgical Aortic Valve Replacement	IDE	Investigational Device Exemption
		DBS	Deep Brain Stimulation	SCS	Spinal Cord Stimulation	ID&E	Inclusion, Diversity and Equity
		DCB	Drug Coated Balloon	SHA	Structural Heart & Aortic	OU	Operating Unit
		DES	Drug Eluting Stent	SVD	Structural Valve Deterioration	VBP	Volume-Based Procurement
		DTM	Differential Target Multiplexed Waveform	TAA	Thoracic Aortic Aneurysm	WE	Western Europe
		ENT	Ear, Nose, & Throat	TAVR	Transcatheter Aortic Valve Replacement	WW	World Wide
		EV-ICD	Extravascular Implantable Cardioverter Defibrillator	TIR	Time In Range		
		GI	Gastrointestinal	URO	Urology		

Medtronic

Engineering the extraordinary

Investor Relations contact information



Ryan Weispenning

Vice President
Head of Investor Relations



Brad Welnick

Vice President
Investor Relations



Gregory Hertz

Senior Director
Investor Relations

investor.relations@medtronic.com



Medtronic